Amneal Pharmaceuticals, Inc. (AMRX) News
Track canonical SquawkNews coverage tagged to AMRX, Amneal Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Amneal Pharmaceuticals Price Target Announced at $27.00/Share by Oppenheimer
Ratings actions from Benzinga: GMT) Amneal Pharmaceuticals Initiated at Outperform by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 12:20 PM UTC
M
Ipsen shares drop after FDA approval of U.S. generic rival
Ipsen shares fell 6.6% to a seven-month low of 145.60 euros in morning European trade after the FDA approved a U.S. generic competitor to Ipsen’s flagship hormone drug earlier than expected.
EQUITY | Sep 21, 2026, 10:02 AM UTC
L
AMRX - Amneal Announces FDA Approval and Launch of Lanreotide Injection
AMRX - Amneal Announces FDA Approval and Launch of Lanreotide Injection
REGULATION | Sep 18, 2026, 08:01 PM UTC
L
Leerink Partners sets $23.00 share price target for Amneal Pharmaceuticals
Leerink Partners announced a $23.00 per-share price target for Amneal Pharmaceuticals, according to ratings actions cited by Benzinga.
EQUITY | Sep 09, 2026, 03:12 PM UTC
H
Amneal Completes Acquisition of Kashiv BioSciences
Amneal acquires Kashiv BioSciences
MNA | Aug 10, 2026, 12:01 PM UTC
L
AMRX -6% after Q2 results
AMRX -6% after Q2 results
EARNINGS | Jul 30, 2026, 01:34 PM UTC
H
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bl
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bldr bmy bud ccc cfr chkp ci cmco cnk cnx crh crox crs csw cwt dar dfin dsx dtm ee
EARNINGS | Jul 30, 2026, 11:18 AM UTC
L
AMRX Amneal Pharmaceuticals RESULTS: Q2, Q2 Net Income $58M, Q2 ADJ EPS $0.3 vs. EST $0.22, Q2 REV $796M, Q2 ADJ EBITDA $206M
AMRX Amneal Pharmaceuticals RESULTS: Q2, Q2 Net Income $58M, Q2 ADJ EPS $0.3 vs. EST $0.22, Q2 REV $796M, Q2 ADJ EBITDA $206M
EARNINGS | Jul 30, 2026, 10:02 AM UTC
L
Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050
Amneal Pharmaceuticals (NASDAQ: AMRX ) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $3.050 billion-$3.150 billion to $3.100 billion-$3.200 bil
EARNINGS | Jul 30, 2026, 10:01 AM UTC
L
AMRX - Amneal Reports Second Quarter 2026 Financial Results
AMRX - Amneal Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 30, 2026, 10:00 AM UTC
L
AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO
AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO
EQUITY | Jul 22, 2026, 12:51 PM UTC
L
AMRX Amneal expands iohexol injection portfolio with U.S. FDA approval of additional strengths and presentations Amneal Pharma - to launch n
AMRX Amneal expands iohexol injection portfolio with U.S. FDA approval of additional strengths and presentations Amneal Pharma - to launch new iohexol injection products in Q3 2026
REGULATION | Jul 17, 2026, 12:00 PM UTC
H
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
The U.S. Food and Drug Administration (FDA) on Monday named seven companies selected for its FDA PreCheck Pilot Program. The initiative aims at strengthening domestic pharmaceutical manufacturing, improving the resilienc
MACRO | Jun 30, 2026, 02:17 PM UTC
L
US FDA selects seven participants for precheck pilot program to advance US drug manufacturing
Names include Amneal, Cellares, Eli Lilly, Fujifilm, Kriya, Kyowa Kirin and Regeneron
REGULATION | Jun 29, 2026, 08:34 PM UTC